| Exploiting the folate receptor α in oncology M Scaranti, E Cojocaru, S Banerjee, U Banerji Nature reviews clinical oncology 17 (6), 349-359, 2020 | 337 | 2020 |
| Telemedicine during the COVID-19 pandemic: impact on care for rare cancers A Smrke, E Younger, R Wilson, O Husson, S Farag, E Merry, ... JCO global oncology 6, 1046-1051, 2020 | 107 | 2020 |
| The activity of chemotherapy in inflammatory myofibroblastic tumors: a multicenter, European retrospective case series analysis GG Baldi, M Brahmi, S Lo Vullo, E Cojocaru, O Mir, M Casanova, ... The Oncologist 25 (11), e1777-e1784, 2020 | 34 | 2020 |
| A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer. ER Plummer, RS Kristeleit, E Cojocaru, NM Haris, L Carter, RH Jones, ... Journal of Clinical Oncology 37 (15_suppl), 3094-3094, 2019 | 33 | 2019 |
| Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy F Chamberlain, E Cojocaru, M Scaranti, J Noujaim, A Constantinou, ... Medical Oncology 37, 1-8, 2020 | 24 | 2020 |
| Personalising treatment for high-grade serous ovarian carcinoma E Cojocaru, CA Parkinson, JD Brenton Clinical Oncology 30 (8), 515-524, 2018 | 23 | 2018 |
| Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? E Cojocaru, C Wilding, B Engelman, P Huang, RL Jones Current Molecular Biology Reports 6, 1-9, 2020 | 22 | 2020 |
| An open label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumors. JS De Bono, E Cojocaru, ER Plummer, T Knurowski, K Clegg, F Ashby, ... Journal of Clinical Oncology 37 (15_suppl), TPS5089-TPS5089, 2019 | 13 | 2019 |
| KIT-Associated familial GIST syndrome: response to tyrosine kinase inhibitors and implications for risk management A Brodey, V Kounnis, L Hawkes, RL Jones, TP McVeigh, E Cojocaru The Oncologist 27 (8), 615-620, 2022 | 10 | 2022 |
| Clinical management and outcomes of primary ovarian leiomyosarcoma–Experience from a sarcoma specialist unit E Cojocaru, GP Gamage, J Butler, DP Barton, K Thway, C Fisher, ... Gynecologic oncology reports 36, 100737, 2021 | 8 | 2021 |
| Telemedicine during the COVID-19 pandemic: impact on care for rare cancers. JCO Glob Oncol 6: 1046–1051 A Smrke, E Younger, R Wilson, O Husson, S Farag, E Merry, ... | 6 | 2020 |
| Efficacy of gemcitabine-based chemotherapy in clear cell sarcoma of soft tissue E Cojocaru, K Thway, C Fisher, C Messiou, S Zaidi, AB Miah, C Benson, ... Anticancer research 40 (12), 7003-7007, 2020 | 5 | 2020 |
| Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland S Gennatas, F Chamberlain, T Carter, S Slater, E Cojocaru, B Lambourn, ... Clinical Sarcoma Research 10, 1-7, 2020 | 5 | 2020 |
| Telemedicine during the COVID-19 pandemic: impact on care for rare cancers. JCO Glob Oncol. 2020; 6: 1046–51 A Smrke, E Younger, R Wilson, O Husson, S Farag, E Merry, ... | 5 | 2020 |
| What’s the latest with investigational drugs for soft tissue sarcoma? E Cojocaru, A Napolitano, C Fisher, P Huang, RL Jones, K Thway Expert Opinion on Investigational Drugs 31 (11), 1239-1253, 2022 | 4 | 2022 |
| Approach to screening for Familial Adenomatous Polyposis (FAP) in a cohort of 226 patients with Desmoid-type Fibromatosis (DF): experience of a specialist center in the UK E Cojocaru, S Gennatas, K Thway, C Fisher, A Smrke, D Strauss, A Hayes, ... Familial cancer, 1-6, 2021 | 4 | 2021 |
| Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer … CA Moss, E Cojocaru, J Hanwell, S Ward, W Xu, M van Zyl, L O'Leary, ... European Journal of Cancer 114, 97-106, 2019 | 4 | 2019 |
| Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre HH Wong, E Cojocaru, J Watkins, S James, T Aloysius, J Harrington, ... Breast Cancer 31 (2), 272-282, 2024 | 1 | 2024 |
| Clinical impact of molecular profiling of cervical cancer (CC) patients (pts) in a dedicated phase I (P1) unit M Scaranti, R Caldwell, MS Miralles, R Shinde, A Pal, JE Ang, A Biondo, ... Annals of Oncology 30, v430, 2019 | 1 | 2019 |
| Tackling immunotherapy resistance: Developing rational combinations of immunotherapy and targeted drugs E Cojocaru, M Scaranti, A Minchom Journal of Immunotherapy and Precision Oncology 2 (2), 23-35, 2019 | 1 | 2019 |
Mariana ScarantiThe Royal Marsden HospitalVerified email at icr.ac.uk
